Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Tesamorelin vs Sermorelin: A Simple Research Comparison

Tesamorelin vs Sermorelin: A Simple Research Comparison

Jun 11, 2026 4 min Growth Hormone
TL;DR
Tesamorelin is FDA-approved for a specific condition in HIV patients, giving it a stronger clinical evidence base. Sermorelin is an older, shorter analog with a different research profile. Neither should be used without medical supervision, and dosing data from studies varies widely.

Two Peptides, One Family

Tesamorelin and Sermorelin are both growth hormone releasing hormone (GHRH) analogs. That's a mouthful. Simply put: they are man-made versions of a natural signal your body uses to tell the pituitary gland to release growth hormone.

Think of GHRH as a doorbell. Both peptides ring that same doorbell — but they're built differently and have been studied in very different ways.[3]

What Is Tesamorelin?

Tesamorelin is a stabilized synthetic version of GHRH. It has an extra chemical group attached that makes it last longer in the body than natural GHRH.[2] It is the only FDA-approved peptide in this class, cleared specifically to reduce excess belly fat in HIV patients who develop a condition called lipodystrophy — abnormal fat redistribution caused by HIV or its treatments.

A randomized trial found that tesamorelin at 2 mg once daily (subcutaneous injection) significantly reduced visceral fat and liver fat in HIV patients over 12 months, and was well tolerated even in people on modern antiretroviral drugs.[6]

Because it's FDA-approved, tesamorelin has more rigorous human trial data than almost any other peptide in its class. That said, researchers note it has no supporting evidence for uses outside its approved indication — such as orthopaedic or sports performance applications.[4]

What Is Sermorelin?

Sermorelin is an older, shorter GHRH analog. It represents only the first 29 amino acids of natural GHRH — the minimum needed to trigger growth hormone release. Think of it as the skeleton key version of the doorbell signal.

Sermorelin was once FDA-approved for diagnosing growth hormone deficiency in children, but that approval was withdrawn in 2008 for commercial reasons, not safety ones. It continues to appear in research and is listed alongside tesamorelin in anti-doping detection studies because both are prohibited by the World Anti-Doping Agency (WADA).[3]

Recent sports medicine reviews include sermorelin among peptides being studied for musculoskeletal and performance applications, though researchers caution that rigorous human safety data remain scarce.[5]

Quick Comparison

  • FDA approval: Tesamorelin ✅ (HIV lipodystrophy) | Sermorelin ❌ (withdrawn)
  • Research dosing: Tesamorelin — 2 mg/day subcutaneous in clinical trials[6] | Sermorelin — varied; no current standard clinical dose
  • Evidence quality: Tesamorelin has Phase III randomized controlled trial data[6] | Sermorelin evidence is largely older or preclinical[5]
  • Mechanism: Both stimulate the pituitary to release growth hormone via GHRH receptors[3]
  • Sports/ortho use: Neither has validated evidence for musculoskeletal or athletic use[4]
  • Detection: Both are detectable in anti-doping urine tests[3]

How Research Dosing Works — and Why It's Complicated

When you read about peptide dosing, you're almost always reading about doses used in a controlled research setting — not recommendations for general use. The 2 mg daily dose of tesamorelin, for example, comes from trials specifically designed for HIV patients with a defined metabolic condition.[6]

Growth hormone secretagogues like these two peptides — along with ipamorelin and CJC-1295 — activate IGF-1 signaling, which plays a role in tissue repair and metabolism.[1] But experts stress that dosing, frequency, and treatment duration for any use outside approved indications remain unknown.[4]

Using our calculator can help you understand and compare the research dose ranges documented in published studies. It is a reference tool, not a prescribing guide.

So How Do You Choose What to Read About?

Start with your goal. If you're researching the metabolic effects of GHRH analogs in HIV-related conditions, tesamorelin has the deeper clinical literature. If you're exploring the history of GHRH analogs or comparing older vs. newer synthetic structures, sermorelin is a useful starting point.

If you're a clinician or researcher interested in sports medicine or musculoskeletal repair, be aware that both peptides appear in that literature — but current reviews consistently flag a lack of human clinical trial evidence for those applications.[5]

Peptide science is moving fast. New reviews from orthopaedic and sports medicine fields are catching up, but they keep arriving at the same honest conclusion: promising signals, not enough human data yet.[1]

All content on PeptideDosageCharts is for research and educational purposes only. Nothing here is medical advice. Always consult a qualified healthcare provider.

Sources

  1. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026. PMID 41490200.
  2. Tesamorelin. — , 2012. PMID 31644039.
  3. Advances in the detection of growth hormone releasing hormone synthetic analogs. — Drug testing and analysis, 2021. PMID 34665524.
  4. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine, 2026. PMID 41476424.
  5. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.), 2026. PMID 41966639.
  6. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. — AIDS (London, England), 2024. PMID 38905488.
See the dosage chart — Tesamorelin
A growth-hormone-releasing hormone analog studied for visceral fat reduction.
Tesamorelin

FAQ

Is Tesamorelin the same as Sermorelin?
No. Both are synthetic versions of the body's growth hormone releasing hormone (GHRH), but they have different structures. Tesamorelin is a longer, stabilized analog with FDA approval for a specific HIV condition. Sermorelin is a shorter, older analog whose FDA approval was withdrawn in 2008 for commercial reasons. They work through the same basic mechanism but have very different research histories.[3]
What dose of Tesamorelin was used in clinical research?
The most cited clinical research used 2 mg of tesamorelin injected subcutaneously once daily. This dose was studied over 12 months in HIV patients with excess visceral fat and was found effective and well tolerated in that specific population.[6] Doses in other contexts are not established through comparable human trial evidence.
Are Tesamorelin or Sermorelin banned in sports?
Yes. Both are prohibited by the World Anti-Doping Agency (WADA). Researchers have developed urine tests capable of detecting both peptides and their metabolites at concentrations of roughly 1 ng/ml or less, meaning detection is increasingly sensitive and reliable.[3]
Can these peptides help with muscle repair or athletic performance?
Current evidence does not support that use for either peptide. Multiple recent reviews from sports medicine and orthopaedic journals conclude that tesamorelin has no supporting orthopaedic evidence, and that rigorous human safety data for sermorelin in athletic contexts are scarce.[4][5] Researchers call for proper clinical trials before any recommendations can be made.
For research and educational use only. Not medical advice.